A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple Myeloma
NCT04398485
Age 18 +
Sex Both
Phase Phase 1
Third Opinion Trial Synopsis
This study is trying to figure out how much ION251 people with multiple myeloma can safely take and what amount would be best for Phase 2 testing.
This study is trying to figure out how much ION251 people with multiple myeloma can safely take and what amount would be best for Phase 2 testing.
Third Opinion AI Generated Synopsis
Trial Summary
The purpose of this study is to determine the maximum-tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of ION251 in patients with relapsed/refractory multiple myeloma.
The purpose of this study is to determine the maximum-tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of ION251 in patients with relapsed/refractory multiple myeloma.
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
